E75.240 Niemann-Pick disease type A

Name of the Condition

• Niemann-Pick disease type A (ICD-10 Code: E75.240)

Summary

Niemann-Pick disease type A is a rare, severe lysosomal storage disorder characterized by the abnormal accumulation of sphingomyelin and cholesterol in cells, particularly affecting the liver, spleen, and nervous system. It is the most common and severe form of Niemann-Pick disease, presenting with early-onset neurological decline and progressive organ dysfunction. The condition is part of a broader group of sphingolipid metabolism disorders and is inherited in an autosomal recessive manner.

Causes

This disorder results from mutations in the SMPD1 gene, which encodes the enzyme acid sphingomyelinase. These mutations impair the enzyme's ability to break down sphingomyelin, leading to its buildup in tissues. Inheritance is autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of Niemann-Pick disease type A or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies for SMPD1 mutations.

Symptoms

• Enlarged liver and spleen (hepatosplenomegaly).
• Progressive neurological decline, including developmental delay or regression.
• Muscle weakness, hypotonia, or spasticity.
• Seizures or abnormal eye movements.
• Loss of motor skills or speech.
• Respiratory difficulties in severe cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Key steps include measuring acid sphingomyelinase activity in white blood cells or skin fibroblasts, identifying SMPD1 gene mutations, and assessing organ involvement through imaging or biopsy. Newborn screening may be considered in high-risk populations.

Treatment Options

Treatment focuses on managing symptoms and complications, as there is no cure. Supportive care includes physical therapy, respiratory support, and nutritional management. Enzyme replacement therapy or gene therapy may be under investigation, but no standardized treatments are widely available.

Prognosis and Follow-Up

Prognosis is poor, with most affected individuals not surviving beyond early childhood. Follow-up involves regular monitoring of organ function, neurological status, and growth. Multidisciplinary care with specialists in genetics, neurology, and hepatology is recommended to address evolving needs.

Complications

• Severe neurological deterioration leading to loss of motor and cognitive function.
• Respiratory failure due to muscle weakness or aspiration.
• Liver or spleen dysfunction causing organ failure.
• Increased susceptibility to infections.

Lifestyle & Prevention

• Genetic counseling for families to understand inheritance risks.
• Prenatal testing or carrier screening for at-risk pregnancies.
• Supportive care to maintain quality of life, including adaptive equipment and speech therapy.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden neurological changes, such as loss of consciousness or seizures.
• Severe respiratory distress or difficulty breathing.
• Unexplained organ enlargement or jaundice.

Tips for Medical Coders

• Use E75.240 for Niemann-Pick disease type A, ensuring specificity for the severe, early-onset subtype.
• Document clinical details, such as age of onset, neurological symptoms, and organ involvement, to support coding accuracy.
• Verify that the diagnosis aligns with genetic or enzymatic testing results when available.